2021.07.08.21260162v2.full

Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in... evaluation study as the results naturally reflect the immunity induced by COVID-19... participants for subsequent follow up..

Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in

evaluation study as the results naturally reflect the immunity induced by COVID-19

participants for subsequent follow up The present report focused on the period from

The study was approved by the Institutional Review Board of HTD and the Oxford

98.1% (102/104) at 14 days after the second dose, and then slightly dropped to 94.7%

our study were negligible, especially in terms of the sero-conversion rate None of our

durability of both cellular and humoral immune responses should be further explored

Table 1: Demographics of the study participants

Whole group (N=554) Subgroup (N=104) Subgroup (N=94)

Table 2: The proportion of study participants with detectable neutralizing antibodies after

vaccination

Notes to Table 2: *for comparison between males and females, NA: non-applicable, **

n=94 (male: 22 and females: 72)

Total (N=554)

Male (N=136)

Female (N=418)

(N=104)

Male (N=25)

Female (N=79)

P value*

Month 3 after the first

dose**

Figure 1

Figure 2

A B

C

Figure 3

List of groups prioritized for COVID-19 vaccination in Vietnam

Supplementary Figure 1: Probability of having detectable neutralizing antibodies among the study participants selected for assessment of the impact of the second dose A) At 2 and

4 weeks after the first dose (n=104), B) Before the second dose (i.e.6 weeks after the first dose) and 2 weeks after the second dose (n=104) and C) at month 3 after the first dose

(n=94) Shaded areas indicate 95% of confident intervals

Supplementary Figure 2: Association between neutralizing antibody levels and gender A) At 2 and 4 weeks after the first dose of the whole group (n=554), B) From baseline to

month three after the first dose of the subgroup